# Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Canonical URL: https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares
Ticker: ELVN
Company: Enliven Therapeutics
Source: Enliven Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.enliventherapeutics.com
## Summary

BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten

## Article Body
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten
## Recent Company News
- 2026-06-25 13:46 EST — [Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Enliven Therapeutics
- 2026-06-25 13:46 EST — [Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Enliven Therapeutics
- 2026-06-25 13:46 EST — [Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Enliven Therapeutics
- 2026-06-25 13:46 EST — [Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-updated-positive-phase-1-clinical-data-and-alignment-with-fda-on-key-phase-3-trial-design-components) — Source: Enliven Therapeutics
- 2026-06-25 13:46 EST — [Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress) — Source: Enliven Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)